Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$11.74 USD

11.74
1,687,846

+0.41 (3.62%)

Updated Nov 5, 2024 03:59 PM ET

After-Market: $11.75 +0.01 (0.09%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.

Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10.00% and 3.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axovant's Gene Therapy Gets Rare Pediatric Disease Status

by Zacks Equity Research

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

Nitish Marwah headshot

4 Breakout Stocks for Explosive Returns

by Nitish Marwah

Choosing breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy promises superlative returns.

Novo Nordisk Raises Sales & Operating Profit Outlook for 2020

by Zacks Equity Research

Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.

Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance

by Zacks Equity Research

The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.

Amicus Therapeutics (FOLD) Down 7.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

by Kinjel Shah

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for July 31st

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9%

by Zacks Equity Research

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.00% and 5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -34.62% and 2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

by Zacks Equity Research

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

Amicus Progresses on Pipeline Development Amid Competition

by Zacks Equity Research

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

Why Is Amicus Therapeutics (FOLD) Up 6% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus Therapeutics, Inc. (FOLD) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Amicus Therapeutics, Inc. (FOLD).